Spruce Biosciences opened lower at $46.00, compared with its previous close of $46.20. In the last trading session, the stock traded between $42.09 and $46.00. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Spruce Biosciences is now worth
$ 12.90
Resulting in a loss of
$ 87.10 (87.10%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-3.62 (-7.83%)
Day High
$46.00
Day Low
$42.09
Day Open
$46.00
Prev Close
$46.20
Volume
37,812
1W Return
-8.01%
1M Return
-1.05%
3M Return
-7.80%
6M Return
-24.50%
1Y Return
-62.20%
Market Cap ($ Mn)
122
PE Ratio
-
PB Ratio
1.99
PEG Ratio
-
ROE
-185.15%
ROCE
-184.35%
EPS (TTM)
$-5.90
1 Week
-8.01%
1 Month
-1.05%
3 Months
-7.80%
6 Months
-24.50%
9 Months
-48.51%
Spruce Biosciences Q3FY26 Results: Loss per share narrows 41.63% YoY
Net loss widened to $24.0 million in Q3FY26 from $8.2 million in Q3FY25. Loss per share narrowed 41.63% YoY to $8.51 from $14.58. R&D expenses surged to $18.1 million from $5.0 million YoY. Cash reserves increased to $87.7 million, funding operations into H2 2027.
3 days agoSpruce Biosciences launches MPS3BStudy.com for TA-ERT programs
Spruce Biosciences launched MPS3BStudy.com for families to register interest in TA-ERT programs. Expanded Access Program and TrAnsform study expected to initiate in Q4 2026. Programs target children with Sanfilippo Syndrome Type B, an ultra-rare neurodegenerative disease. TA-ERT has prior safety data from 22 individuals across three clinical studies.
2mo agoSpruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY
Spruce Biosciences Inc reported Q2 EPS of $(6.68), missing the $(5.80) estimate by 15.17%. Losses widened 90.86% YoY from $(3.50), signaling deteriorating profitability and higher-than-expected operational costs.
3mo agoSpruce Biosciences appoints Jessica Cohen Pfeffer as clinical development VP
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP of Clinical Development to lead efforts for its lead candidate TA-ERT. She brings extensive experience in rare pediatric neurodegenerative disorders from BioMarin. She received an inducement award of 3,800 RSUs vesting over four years.
3mo agoB. Riley initiates coverage on Spruce Biosciences with Buy rating
B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences with a Buy rating and a $160 price target, indicating a positive outlook.
4mo agoSpruce Biosciences CEO to present at B. Riley summit in Boston
Spruce Biosciences, Inc. announced that CEO Javier Szwarcberg will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit on July 16, 2026, in Boston. The company focuses on therapies for neurological disorders, with its lead candidate TA-ERT targeting MPS IIIB. Investors must contact B. Riley Securities to arrange meetings.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Spruce Biosciences is now worth
$ 12.90
Resulting in a loss of
$ 87.10 (87.10%)
Note: Past profits do not guarantee future returns.
